PARPi

DRUG3 trials

Sponsors

Shanghai Gynecologic Oncology Group, University of Miami, Lei Li

Conditions

Breast CancerER-positive Breast CancerEpithelial Ovarian CancerFallopian Tube CancerHER2-negative Breast CancerMetastatic Breast CancerOvarian CancerPrimary Peritoneal Carcinoma

Phase 2

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Active, not recruitingNCT05826964

University of MiamiBreast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer +1

Start: 2023-06-12End: 2029-07-31Target: 24Updated: 2026-01-13

Phase 3

Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)

Not yet recruitingNCT04515602

Shanghai Gynecologic Oncology GroupEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

Start: 2021-01-31End: 2028-01-31Target: 410Updated: 2020-08-27

Unknown Phase

HRD Status Reference Standard Based on WGS

CompletedNCT06490380

Lei LiOvarian Cancer

Start: 2022-12-30End: 2024-06-21Updated: 2024-07-08